ENOV vs. HRMY

Last updated Jun 4, 2026

ENOV (Enovis Corp) and HRMY (Harmony Biosciences Holdings, Inc.) are both stocks. ENOV operates in Specialty Industrial Machinery (Industrials), while HRMY operates in Biotechnology (Healthcare). Over the past 5 years, ENOV returned -22.84%/yr vs -0.67%/yr for HRMY. At a 0.26 correlation, their price movements are largely independent.

Performance

ENOV vs. HRMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Enovis Corp (ENOV) and Harmony Biosciences Holdings, Inc. (HRMY). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ENOV achieves a -19.07% return, which is significantly lower than HRMY's -14.22% return.

ENOV

• 1D: -1.73%
• 1M: -7.63%
• YTD: -19.07%
• 6M: -26.37%
• 1Y: -29.73%
• 3Y*: -27.36%
• 5Y*: -22.84%
• 10Y*: -7.79%

HRMY

• 1D: 3.85%
• 1M: -1.50%
• YTD: -14.22%
• 6M: -13.24%
• 1Y: -9.09%
• 3Y*: -3.02%
• 5Y*: -0.67%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

ENOV vs. HRMY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
ENOV Enovis Corp	-19.07%	-39.29%	-21.67%	4.67%	-32.36%	20.21%	12.80%
HRMY Harmony Biosciences Holdings, Inc.	-14.22%	8.75%	6.53%	-41.38%	29.22%	17.95%	-2.32%

Correlation

The correlation between ENOV and HRMY is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.27
Correlation (3Y) Calculated over the trailing 3-year period	0.25
Correlation (5Y) Calculated over the trailing 5-year period	0.28
Correlation (All Time) Calculated using the full available price history since Aug 20, 2020	0.26

Fundamentals

EPS ENOV : -$26.70 HRMY : $2.48
PS Ratio ENOV : 0.40 HRMY : 2.09
Total Revenue (TTM) ENOV : $2.28B HRMY : $899.11M
Gross Profit (TTM) ENOV : $1.38B HRMY : $688.25M
EBITDA (TTM) ENOV : -$840.37M HRMY : $221.74M

Return for Risk

ENOV vs. HRMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ENOV

ENOV Risk / Return Rank: 17
ENOV Sharpe Ratio Rank: 17
ENOV Sortino Ratio Rank: 19
ENOV Omega Ratio Rank: 20
ENOV Calmar Ratio Rank: 14
ENOV Martin Ratio Rank: 16

HRMY

HRMY Risk / Return Rank: 31
HRMY Sharpe Ratio Rank: 31
HRMY Sortino Ratio Rank: 29
HRMY Omega Ratio Rank: 29
HRMY Calmar Ratio Rank: 31
HRMY Martin Ratio Rank: 32

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ENOV vs. HRMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Enovis Corp (ENOV) and Harmony Biosciences Holdings, Inc. (HRMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ENOV	HRMY	Difference
Sharpe ratio Return per unit of total volatility	-0.55	-0.22	-0.33
Sortino ratio Return per unit of downside risk	-0.53	-0.02	-0.51
Omega ratio Gain probability vs. loss probability	0.94	1.00	-0.06
Calmar ratio Return relative to maximum drawdown	-0.74	-0.26	-0.48
Martin ratio Return relative to average drawdown	-1.17	-0.49	-0.69
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ENOV vs. HRMY - Sharpe Ratio Comparison

The current ENOV Sharpe Ratio is -0.55, which is lower than the HRMY Sharpe Ratio of -0.22. The chart below compares the historical Sharpe Ratios of ENOV and HRMY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ENOV	HRMY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.55	-0.22	-0.33
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.59	-0.01	-0.58
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.18	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.06	-0.05	-0.01

Drawdowns

ENOV vs. HRMY - Drawdown Comparison

The maximum ENOV drawdown since its inception was -83.36%, which is greater than HRMY's maximum drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for ENOV and HRMY.

Drawdown Indicators

	ENOV	HRMY	Difference
Max Drawdown Largest peak-to-trough decline	-83.36%	-68.48%	-14.88%
Max Drawdown (1Y) Largest decline over 1 year	-40.29%	-34.49%	-5.80%
Max Drawdown (3Y) Largest decline over 3 years	-67.26%	-50.81%	-16.45%
Max Drawdown (5Y) Largest decline over 5 years	-76.46%	-68.48%	-7.98%
Max Drawdown (10Y) Largest decline over 10 years	-76.46%	—	—
Current Drawdown Current decline from peak	-83.28%	-47.30%	-35.98%
Average Drawdown Average peak-to-trough decline	-45.92%	-35.20%	-10.72%
Ulcer Index Depth and duration of drawdowns from previous peaks	25.34%	18.69%	+6.65%

Volatility

ENOV vs. HRMY - Volatility Comparison

Enovis Corp (ENOV) has a higher volatility of 19.66% compared to Harmony Biosciences Holdings, Inc. (HRMY) at 10.05%. This indicates that ENOV's price experiences larger fluctuations and is considered to be riskier than HRMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ENOV	HRMY	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.66%	10.05%	+9.61%
Volatility (6M) Calculated over the trailing 6-month period	39.94%	30.17%	+9.77%
Volatility (1Y) Calculated over the trailing 1-year period	54.08%	41.40%	+12.68%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	38.61%	50.04%	-11.43%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	42.30%	52.40%	-10.10%

Dividends

ENOV vs. HRMY - Dividend Comparison

Neither ENOV nor HRMY has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

ENOV vs. HRMY - Profitability Comparison

The chart below illustrates the profitability comparison between Enovis Corp and Harmony Biosciences Holdings, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ENOV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Enovis Corp reported a gross profit of 365.49M and revenue of 589.15M. Therefore, the gross margin over that period was 62.0%.

HRMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a gross profit of 170.88M and revenue of 215.39M. Therefore, the gross margin over that period was 79.3%.

ENOV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Enovis Corp reported an operating income of 6.53M and revenue of 589.15M, resulting in an operating margin of 1.1%.

HRMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported an operating income of 37.29M and revenue of 215.39M, resulting in an operating margin of 17.3%.

ENOV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Enovis Corp reported a net income of -8.76M and revenue of 589.15M, resulting in a net margin of -1.5%.

HRMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a net income of 32.49M and revenue of 215.39M, resulting in a net margin of 15.1%.

Frequently Asked Questions

Can I hold both ENOV and HRMY in my portfolio?

ENOV and HRMY have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ENOV or HRMY?

ENOV has higher volatility (19.66%) compared to HRMY (10.05%). In terms of maximum drawdown, ENOV dropped -83.36% vs HRMY's -68.48%.

Which has better risk-adjusted returns?

HRMY currently has the higher Sharpe Ratio (-0.22 vs -0.55), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.